Hegedus L, et al. - Physicians designed this study to describe the changes in serum levels of calcitonin in liraglutide- and placebo-treated patients in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial over a 3.5–5-year period. No evidence of a difference in calcitonin concentrations was found between the liraglutide and placebo groups. In the liraglutide group, no C-cell malignancies occurred.